PE20040797A1 - Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion - Google Patents

Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion

Info

Publication number
PE20040797A1
PE20040797A1 PE2003001178A PE2003001178A PE20040797A1 PE 20040797 A1 PE20040797 A1 PE 20040797A1 PE 2003001178 A PE2003001178 A PE 2003001178A PE 2003001178 A PE2003001178 A PE 2003001178A PE 20040797 A1 PE20040797 A1 PE 20040797A1
Authority
PE
Peru
Prior art keywords
growth hormone
human growth
sticked
preparation
terminal
Prior art date
Application number
PE2003001178A
Other languages
English (en)
Inventor
Rory F Finn
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20040797A1 publication Critical patent/PE20040797A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN CONJUGADO DE HORMONA DE CRECIMIENTO HUMANA-PEG DE FORMULAS I o II, EN LA QUE n Y m SON, INDEPENDIENTEMENTE ENTRE SI, UN NUMERO ENTERO ENTRE 1 A 10; R ES UNA HORMONA DE CRECIMIENTO HUMANA u HORMONA DE CRECIMIENTO HUMANA METIONILO; EN DONDE DICHA HORMONA DE CRECIMIENTO HUMANA COMPRENDE UNA SECUENCIA AMINOACIDICA DE SEC Nº ID 1 Y QUE SE CONJUGA CON EL POLIETILENGLICOL (PEG) A TRAVES DE UNA FENILALANINA AMINOTERMINAL Y EN LA QUE CADA PEG TIENE UN PESO APROXIMADO DE 20 Kda. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE DICHO CONJUGADO Y AL MENOS UN VEHICULO FARMACEUTICAMENTE ACEPTABLE Y QUE ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS DE CRECIMIENTO O DESARROLLO DEBIDO A UNA DEFICIENCIA DE HORMONA DE CRECIMIENTO (DHC), SINDROME DE TURNER, INSUFICIENCIA CRONICA RENAL
PE2003001178A 2002-11-20 2003-11-20 Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion PE20040797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42782302P 2002-11-20 2002-11-20

Publications (1)

Publication Number Publication Date
PE20040797A1 true PE20040797A1 (es) 2004-12-10

Family

ID=32825103

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001178A PE20040797A1 (es) 2002-11-20 2003-11-20 Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion

Country Status (9)

Country Link
US (1) US20040127417A1 (es)
AR (1) AR042103A1 (es)
GT (1) GT200300250A (es)
NL (3) NL1024831C2 (es)
PA (1) PA8588901A1 (es)
PE (1) PE20040797A1 (es)
SV (1) SV2004001674A (es)
TW (1) TWI281864B (es)
UY (1) UY28085A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BR0314172A (pt) 2002-09-09 2005-07-26 Nektar Therapeutics Al Corp Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004060300A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
BR0317742A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de interferon-beta com potência biológica aumentada
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
BRPI0507436A (pt) * 2004-02-09 2007-07-03 Pharmacia Corp conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados
US20080182783A1 (en) * 2004-10-18 2008-07-31 Novo Nordisk A/S Growth Hormone Conjugates
WO2006042847A2 (en) * 2004-10-18 2006-04-27 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
AU2006286486A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
EP2040757A2 (en) * 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3355384A1 (en) * 2017-01-31 2018-08-01 Universite De Liege Flexible thin-films for battery electrodes
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE122006000003I1 (de) * 1995-09-21 2006-05-04 Genentech Inc Varianten des Menschlichen Wachstumshormons
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
SE9904502D0 (sv) * 1999-12-09 1999-12-09 Pharmacia & Upjohn Ab Production of peptides

Also Published As

Publication number Publication date
PA8588901A1 (es) 2005-02-04
TW200418878A (en) 2004-10-01
NL1028837A1 (nl) 2005-08-30
US20040127417A1 (en) 2004-07-01
NL1028837C2 (nl) 2006-08-14
GT200300250A (es) 2004-08-18
UY28085A1 (es) 2004-07-30
SV2004001674A (es) 2004-05-17
NL1032282C2 (nl) 2007-03-09
AR042103A1 (es) 2005-06-08
TWI281864B (en) 2007-06-01
NL1024831A1 (nl) 2004-05-26
NL1032282A1 (nl) 2006-11-07
NL1024831C2 (nl) 2005-04-28

Similar Documents

Publication Publication Date Title
PE20040797A1 (es) Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
BR9815159A (pt) Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio
BRPI0309868B1 (pt) métodos de preparação de uma composição de reduzida fração conjugada inferior
LU92237I2 (fr) Pegloticase et toute forme thérapeutique équivalente protégée par le brevet de base
AR008378A1 (es) Conjudados de interferon
BR0209685A (pt) Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
UY26228A1 (es) Derivados de eritropoyetina ley 17.164 art. 127
DK0966297T3 (da) Regulering af gastroinstestinal motilitet
DE60235010D1 (de) Monodisperse gemische aus calcitonin-arzneimittel-oligomer-konjugaten mit polyethylenglycol, ihre verwendung und verfahren zu ihrer herstellung
CY1117358T1 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
ES2164251T3 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
AR047062A1 (es) Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos
NO20074267L (no) Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid
BRPI0417341A (pt) fator ix glicopeguilado
WO2001058493A8 (en) Conjugates of follicle stimulating hormones
AR046960A1 (es) Metodos para producir los conjugados portadores de peptidos inmunogenicos
BR0012200B1 (pt) composição de peptídeo para o tratamento de disfunção sexual e composição farmacêutica para o tratamento de disfunção sexual em um mamífero.
CA2329754A1 (en) Peptide composition as immunogen for the treatment of allergy
DK199901377A (da) Rekombinant pseudomonas exotoxin og opbygning af aktivt immunotoxin
DE69130741T2 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung
NO975547L (no) Vaksiner med modifiserte meningokokk/polysakkarid-konjugater
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
DE69231663D1 (de) Konjugate bestehend aus polysaccharid und protein
EP1242115A4 (en) CHEMICALLY PROGRAMMABLE IMMUNITY
WO1995011977A3 (en) A NEW RIBOSOME-INACTIVATING PROTEIN ISOLATED FROM THE PLANT $i(BRYONIA DIOICA)

Legal Events

Date Code Title Description
FC Refusal